research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
Search
for
Sort by
Research
990-1000 / 1000+ results
research Chemotherapy in Gynecologic Malignancy
Chemotherapy provides symptom relief and extends life in 30-50% of gynecological cancer cases, but has only cured choriocarcinoma.
research VIJAYA-The one who fights to win
Vijaya successfully fought stage 2A breast cancer with surgery, chemotherapy, radiotherapy, and hormone therapy, while advocating for support groups.
research Intralesional Triamcinolone Acetonide in the Management of Acne Keloidalis Nuchae
Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
research Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment
Cetuximab can cause unusual hair growth and hair loss.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Combination therapy profoundly improved skin flap survival by modulating KATP channels and nitric oxide
The combination of azelaic acid, minoxidil, and caffeine significantly increased the survival of skin flaps by affecting certain body channels and nitric oxide levels.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Present Chemotherapy Induced Alopecia and Research in Future
Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.
research Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
Patients with alopecia areata on ritlecitinib responded well to tetanus and meningococcal vaccines.